<DOC>
	<DOCNO>NCT00063089</DOCNO>
	<brief_summary>Altastaph develop help removal S. aureus bloodstream . The main objective study test safety behavior Altastaph patient S.aureus bacteremia continue fever</brief_summary>
	<brief_title>Safety Behavior S. Aureus Immune Globulin Intravenous ( Human ) , Altastaph Patients With S. Aureus Bacteremia Continuing Fever</brief_title>
	<detailed_description>Staphylococcus aureus recognize important community - acquire nosocomial pathogen . Because common cause osteomyelitis , endocarditis , meningitis , S. aureus infection lead considerable morbidity mortality . The main objective study test safety pharmacokinetics Altastaph patient S. aureus bacteremia persistent fever . This study also assess efficacy Altastaph versus control .</detailed_description>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Male female great equal 7 year age Weight le equal 150 kilogram Subjects willing complete full duration study , include follow visit day 42 Life expectancy enable subject complete duration study Female subject childbearing potential , negative serum pregnancy test prior first infusion study material . Female subject childbearing potential must agree use effective method birth control throughout study . Abstinence consider adequate birth control measure . Female subject nonchildbearing potential must history hysterectomy , bilateral surgical radiationinduced oophorectomy , tubal ligation evidence post menopausal status Subject , legal guardian ( ) medical power attorney must give write informed consent/ assent S. aureus bacteremia persistent fever . S. aureus bacteremia define first blood culture positive S. aureus ( index blood culture ) . Persistent fever ( qualify fever ) define temperature ( great equal 100.4F great equal 38C ) occur least 24 hour index temperature record index blood culture draw Absolute Neutrophil Count ( ANC ) great equal 500 x 10^9 cells/L Subjects malignancy may participate : ( 1 ) The malignancy solid tumor ( i.e . lymphoma , leukemia , etc . ) ( 2 ) The tumor metastasize bone marrow Known hypersensitivity previous anaphylaxis polysaccharide polysaccharideconjugate vaccine component Altastaph Profound disability , assess investigator , would prevent participation study Known IgA deficiency Known HIV infection CD4 count &lt; 200 cells/L Presence condition , opinion investigator , place subject undo risk potentially jeopardize quality data generate Pregnancy breast feed Use investigational drug biologic four week prior screen study . The exception use investigational antineoplastic product , : ( 1 ) The product expect result sever prolong immunosuppression ( 2 ) The product , , immunologicallybased ( e.g . antitumor/ monoclonal antibody , cancer vaccine interleukin</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Staphylococcal infection</keyword>
	<keyword>Gram positive bacteria</keyword>
	<keyword>Staphylococcus</keyword>
	<keyword>Staphylococcus aureus</keyword>
</DOC>